Leonard Frank X - Mar 3, 2023 Form 4 Insider Report for NovoCure Ltd (NVCR)

Role
President, CNS Cancers US
Signature
Steven Robbins, as attorney in fact for Leonard, Frank X.
Stock symbol
NVCR
Transactions as of
Mar 3, 2023
Transactions value $
-$1,028,165
Form type
4
Date filed
3/7/2023, 03:52 PM
Previous filing
Mar 6, 2023
Next filing
Jan 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVCR Ordinary Shares Sale -$335K -4.4K -6.49% $76.16 63.5K Mar 3, 2023 Direct F1
transaction NVCR Ordinary Shares Sale -$67.6K -888 -1.4% $76.16 62.6K Mar 3, 2023 Direct F1
transaction NVCR Ordinary Shares Sale -$450K -6K -9.59% $75.00 56.6K Mar 7, 2023 Direct F2
transaction NVCR Ordinary Shares Sale -$175K -2.32K -4.09% $75.59 54.3K Mar 7, 2023 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2 On the transaction date, pursuant to a Rule 10b5-1 trading plan adopted by the reporting person, the reporting person sold 6,003 shares in multiple trades at prices ranging from $74.33 to $75.32. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
F3 On the transaction date, pursuant to a Rule 10b5-1 trading plan adopted by the reporting person, the reporting person sold 2,315 shares in multiple trades at prices ranging from $75.33 to $75.94. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.